Close Menu

More articles about Molecular Diagnostics

Ionian is developing a molecular diagnostics platform that will run assays designed for use in the developing world.

Enzo aims to market the ColonSentry test in NY and NJ.

Mayo Clinic has licensed rights to IP that will be used in its test for for diagnosing and classifying amyloidosis.

Asuragen will seek FDA clearance for the CML test, which Life Technologies will distribute.

Nanosphere is seeking FDA clearance for the assay, which would be used to provide early diagnosis of myocardial infarction and risk stratification for acute coronary syndromes.

Roche becomes the latest of a handful of vendors to get an EUA from the FDA to sell its 2009 H1N1 flu assay to CLIA labs.

The Berlin-based firm trimmed its loss on higher sales from collaborations, licenses, and partnerships.

The firm said increased instrument sales still should lead to a full-year revenue boost.

Qiagen gains exclusive rights to sell three molecular assays aimed at equine bacterial diseases.

Nearly all of Exact Sciences' revenues came from license fees, as the firm continues to develop its assay for colorectal cancer.

The guidance document is intended to help manufacturers develop diagnostic tests for the 2009 H1N1 influenza virus, and provides information regarding filing for Emergency Use Authorization.

On-Q-ity is developing a cancer diagnostic platform that combines monitoring DNA repair biomarkers to predict treatment response and microfluidic chips that enable the capture, enumeration, and characterization of circulating tumor cells in a patient's bloodstream.

The firm will use Medical Therapies' midkine patent portfolio to develop lung cancer diagnostics.

Xenomics is seeking up to $300 million in damages and the termination of its licensing deal with Sequenom.

Gen-Probe got the EUA for a test made by Prodesse for detecting H1N1.

The lawsuit claims Nanosphere has infringed Eppendorf's patent covering its Silverquant microarray technology.

The pact with Geisinger and its lab services company covers heart diagnostics and disease management testing.

The license gives Micronics the rights to use and sell molecular diagnostic technologies using Biosearch's fluorophores and quencher dyes.

According to Quest, Scripps Health is "the first health system in the US to deploy this genetic testing service for coronary stent patients" receiving Plavix. The testing will initially be available for stent procedure patients presenting to Scripps Green Hospital in San Diego.

The settlement ends a one-year-old dispute regarding mass-spec based patents held by Sequenom.


The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.